MHH Logo

Institute of Experimental Diabetes Research - Niedersachsen-Professor


Professor Sigurd Lenzen, MD - Niedersachsen-Professor of Experimental Diabetes Research



Hannover Medical School

Institute of Experimental Diabetes Research

OE 4360

Carl-Neuberg-Str. 1

30625 Hannover / Germany

Tel. : +49 511 532 6525

Fax : +49 511 532 3584



Research focuses:

  • Cell and molecular biology of the islets of Langerhans
  • Mechanisms of glucose-induced insulin secretion and signal recognition in pancreatic beta cells
  • Molecular biology of glucose transport (GLUT2 glucose transporter) and glucose phosphorylation (glucokinase) in beta cells and liver
  • Mechanisms of selective beta cell dysfunction and death by necrosis and apoptosis through cytokines (T1DM) and lipotoxicity (T2DM)
  • Importance of cytoprotective enzymes for protection against beta cell death
  • Mechanisms of diabetogenic action of alloxan and streptozotocin
  • Bioengineering of insulin-producing surrogate cells through differentiation of stem cells
  • Mechanisms of action of antihyperglycemic drugs
  • Gene therapy of insulin-dependent diabetes mellitus (IDDM)
  • Type 1 and type 2 diabetes animal models
  • The LEW.1AR1.-iddm rat (IDDM rat) as an animal model of human T1DM and the characterisation of the underlying pathomechanisms of beta cell death in autoimmune diabetes
  • Immunomodulatory therapies for prevention and cure of T1DM

Recent Reviews:

  1. Waldhäusl W, Lenzen S. Kohlenhydrate, endokrines Pankreas, Diabetes. In: Pathophysiologie. Molekulare und zelluläre Pathomechanismen, Kapitel 14, Kohlenhydrate, Wick G, Schwarz S, Peterlik M, Förster O, Schauenstein (Eds). Gustav Fischer Verlag, Stuttgart, pp. 14-1-14-19, 2007 (Book Chapter)
  2. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 51, 216-226, 2008 (Review)
  3. Lenzen S. Oxidative stress: the vulnerable beta cell. Biochem Soc Trans 36, 343-347, 2008 (Review)
  4. Gehrmann W, Elsner M, Lenzen S. Role of metabolically generated reactive oxigen species for lipotoxicity in pancreatic beta cells. Diabetes Obes Metab 12 (Suppl. S2), 149-158, 2010 (Review)
  5. Lenzen S. Die Rolle der Betazelle im Diabetes [The beta cell in diabetes]. Dtsch Med Wochenschr 136, 1123-1127, 2011 (Review)
  6. Naujok O, Burns C, Jones PM, Lenzen S. Insulin-producing surrogate beta cells from embryonic stem cells - Are we there yet? Mol Ther 19, 1759-1768, 2011 (Review)
  7. Naujok O, Lenzen S. Pluripotente Stammzellen zur Zellersatztherapie des Diabetes Mellitus. Dtsch Med Wochenschr 2012 in press (Review)
  8. Lenzen S. Chemistry and biology of reactive species with special reference to the antioxidative defence status in pancreatic β-cells. Biochim Biophys Acta 2017 (Review)
  9. Lenzen S. Animal models of human type 1 diabetes for evaluating combination therapies and successful translation to the patient with type 1 diabetes. Diabetes Metab Res Rev 33, 2017 Jul 10. doi: 10.1002/dmrr.2915. Epub 2017 Aug 2 (Review)
  10. Lenzen S. An editorial on the article 'Patents in the diabetes area in the years 2008-2016'. Expert Opin Ther Pat. 2018 Jan 15:1-2. doi: 10.1080/13543776.2018.1427734 (Review)

For original publications from the Institute of Clinical Biochemistry at the MHH:

see "PubMed" (link) on the internet under "Lenzen-S"